RCS - Creo Medical Group - MicroBlate™ Flex clinical study

Creo MedicalAnnouncement

31/03/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230331:nRSe8557Ua&default-theme=true

RNS Number : 8557U  Creo Medical Group PLC  31 March 2023

 

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

MicroBlate™ Flex clinical study in lung lesion microwave ablation

Multicentre observational study representing first in human use of the device
for

soft tissue lung lesions

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the
emerging field of surgical endoscopy, announces a multi-site clinical study
(the "Study") to evaluate the safety and feasibility of MicroBlate™ Flex,
Creo's bronchoscopic microwave ablation device, for the treatment of lung
lesions.

 

MicroBlate™ Flex is a new soft tissue ablation device, designed with the aim
of being able to ablate nodules and tumours in several tissue types using the
highest frequency MW energy used for tumour ablation. Lung cancer is the most
common cancer in men and the second most common cancer in women 1 , and
treatment options are currently sub optimal and typically involve
chemotherapy, radiation therapy, surgery or a combination thereof. The size
and flexibility of MicroBlate™ Flex offer patients the prospect of a
significantly less invasive procedure when treating lung tumours than
alternatives.  MicroBlate™ Flex also has potential to be used to treat a
number of other conditions, where a small diameter flexible device enables
access into otherwise inaccessible regions of the body.

 

The Study is the first of a number of planned studies designed by Creo, in
conjunction with Kamaptive partners, in respect of Creo's suite of ablation
devices during 2023 and beyond. The Study will initially take place in the UK,
and may expand to up to a total of six sites across Europe, with the potential
to expand into the United States.

 

As principal investigator, Pallav L Shah, MD, of the Royal Brompton and
Harefield NHS Foundation Trust, has commenced the process to recruit patients
to undergo treatment. The patients recruited will represent the first in-human
cases for Creo's MicroBlate™ Flex device and will have regular follow-up
assessments for twelve months post-procedure to monitor their progress. The
first case is expected to take place during Q2 2023.

 

Full details of the Study can be found at:
 https://clinicaltrials.gov/ct2/show/NCT05786625
(https://clinicaltrials.gov/ct2/show/NCT05786625)

 

 

Craig Gulliford, Chief Executive Officer of Creo, commented: "It is pleasing
that the first human use of MicroBlate™ Flex, a technology designed and
developed in the UK, is likely to take place in the UK as part of this Study.
The Study aims to build an evidence base as a pioneering device for the
treatment of lung lesions. MicroBlate™ Flex enables a less invasive,
endoscopic alternative to treat lung lesions as a first-line option, as well
as treatment of patients not eligible for surgery."

 

Enquiries:

 

 Creo Medical Group plc                              www.creomedical.com (http://www.creomedical.com)
 Richard Rees (CFO)                                  +44 (0)1291 606 005

 Cenkos Securities plc                               +44 (0)20 7397 8900
 Stephen Keys / Camilla Hume (NOMAD)
 Michael Johnson / Russell Kerr (Sales)

 Numis Securities Limited (Joint Broker)             +44 (0)20 7260 1000

 Freddie Barnfield / James Black / Duncan Monteith

 Walbrook PR                                         Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
 Paul McManus / Sam Allen                            Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258

 Phillip Marriage                                    +44 (0)7867 984 082

 

 

About Creo Medical

Creo Medical is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less-invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

 

 

 1  https://www.wcrf.org/cancer-trends/lung-cancer-statistics/

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAEDEDENDEAA